Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2010

View Archived Issues

Dengue virus therapy AVI-6006 shows promise in animal models

Intranasal GI.1 norovirus virus-like particle vaccine is safe and efficacious in healthy volunteers

Quadrivalent Fluzone QIV is as safe and immunogenic as trivalent flu vaccines

AN-3661 is efficacious against Plasmodium infections in mice

Marina Biotech receives approval for CEQ-508 trial in familial adenomatous polyposis

Advanced Life Sciences enters into CRADA to advance Restanza for malaria

Bayer Schering Pharma claims new neutrophil elastase inhibitors

Bristol-Myers Squibb and Simcere to jointly develop BMS-817378

FDA approves Cymbalta for management of chronic musculoskeletal pain

New cytotoxic agents described for colon cancer therapy

Provectus plans course of action for approval of PV-10 in Australia

Advaxis and NCI enter into CRADA to develop Listeria vaccines

Shire provides update on progress of third quarter 2010

Italian scientists present new inhibitors of HCV NS5B

Phase III data reported on crofelemer for diarrhea in HIV-infected persons on antiretroviral therapy

Sanofi-aventis presents new inhibitors of PDE7 and/or PDE8

Boehringer Ingelheim identifies new reverse transcriptase inhibitors

Alnylam grants property license to Tekmira for TKM-Ebola

Nicotine vaccine NIC-002 enters phase II study

FDA approves once-daily Kombiglyze XR tablets for type 2 diabetes

FDA clears Vitros intact parathyroid hormone assay

Primary endpoint met in phase IIa vidofludimus trial in inflammatory bowel disease

Kuros regains rights to KUR-112, KUR-212 and KUR-213

Phase IIb data reported on LIPO-102 for selective nonablative fat reduction

BMK.1 inhibitor XMD-8-92 inhibits tumor growth in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...